Skip to the main content.

Cell and Gene Therapy Series. Part 3 - Clusters, Megadeals, "Cellicon Valley" and the "Golden Triangle

Dr. Dave Seaward : 28 February 2022

Cell and Gene Therapy Series. Part 3 - Clusters, Megadeals,

In this third instalment to our cell and gene blog series, author Dave Seaward explains where most ATMP technology is being delivered as well as providing insight into why.

Click here to gain an understanding of why investors believe significant returns will be made from these technologies.
Formulation Freedom in Clinical Development: Why Fill2Weight Matters

Formulation Freedom in Clinical Development: Why Fill2Weight Matters

Chris Webster: 1 June 2026

In early-stage pharmaceutical development, poor powder flow is rarely the root issue, it’s simply a symptom. The real challenge for formulation...

Read More
Pouching solutions for sterile and moisture-sensitive devices

Pouching solutions for sterile and moisture-sensitive devices

David Phasey: 20 May 2026

Pouches are widely used in medical device packaging to provide a sterile barrier when the device itself, or its primary container, cannot inherently...

Read More
Interview with Founder Tom Bailey: Blister Dose Delivery Uniformity (DDU)

Interview with Founder Tom Bailey: Blister Dose Delivery Uniformity (DDU)

Georgia Lewis: 18 May 2026

Dose Delivery Uniformity (DDU) is one of the most persistent challenges in dry-powder inhaler development, and few have tackled it more directly...

Read More